HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy
CD4+ T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4+ T cells are another specialized subset that plays a fundamental role in the mai...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01081/full |
id |
doaj-4a1c67bc23984cca9d680fc6d4f65167 |
---|---|
record_format |
Article |
spelling |
doaj-4a1c67bc23984cca9d680fc6d4f651672020-11-24T21:21:52ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-05-011010.3389/fimmu.2019.01081447508HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based ImmunotherapyAlexandre Couture0Anthony Garnier1Fabian Docagne2Olivier Boyer3Denis Vivien4Denis Vivien5Brigitte Le-Mauff6Brigitte Le-Mauff7Jean-Baptiste Latouche8Jean-Baptiste Latouche9Olivier Toutirais10Olivier Toutirais11Olivier Toutirais12UNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, FranceInserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, FranceInserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, FranceDepartment of Immunology and Biotherapy, Inserm U1234, Institute for Research and Innovation in Biomedicine, UNIROUEN, Rouen University Hospital, Normandie University, Rouen, FranceInserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, FranceDepartment of Clinical Research, Caen University Hospital, Caen, FranceInserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, FranceDepartment of Immunology and Immunopathology, Caen University Hospital, Caen, FranceUNIROUEN, Inserm U1245, Institute for Research and Innovation in Biomedicine, Normandie University, Rouen, FranceDepartment of Genetics, Rouen University Hospital, Rouen, FranceInserm U1237, Physiopathology and Imaging of Neurological Disorders, Caen University Hospital, Caen, FranceDepartment of Immunology and Immunopathology, Caen University Hospital, Caen, FranceFrench Blood Service (Etablissement Français du Sang), Caen, FranceCD4+ T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4+ T cells are another specialized subset that plays a fundamental role in the maintenance of immune tolerance to self-antigens. Manipulating effector or regulatory CD4+ T cells responses is a promising immunotherapy strategy for, respectively, chronical viral infections and cancer, or severe autoimmune diseases and transplantation. Adoptive cell therapy (ACT) is an emerging approach that necessitates defining robust and efficient methods for the in vitro expansion of antigen-specific T cells then infused into patients. To address this challenge, artificial antigen presenting cells (AAPCs) have been developed. They constitute a reliable and easily usable platform to stimulate and amplify antigen-specific CD4+ T cells. Here, we review the recent advances in understanding the functions of CD4+ T cells in immunity and in immune tolerance, and their use for ACT. We also describe the characteristics of different AAPC models and the way to improve their stimulating functions. Finally, we discuss the potential interest of these AAPCs, both as fundamental tools to decipher CD4+ T cell responses and as reagents to generate clinical grade antigen-specific CD4+ T cells for immunotherapy.https://www.frontiersin.org/article/10.3389/fimmu.2019.01081/fullCD4+ T lymphocytesadoptive cell therapycancerautoimmunityartificial antigen presenting cellsHLA class II molecules |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexandre Couture Anthony Garnier Fabian Docagne Olivier Boyer Denis Vivien Denis Vivien Brigitte Le-Mauff Brigitte Le-Mauff Jean-Baptiste Latouche Jean-Baptiste Latouche Olivier Toutirais Olivier Toutirais Olivier Toutirais |
spellingShingle |
Alexandre Couture Anthony Garnier Fabian Docagne Olivier Boyer Denis Vivien Denis Vivien Brigitte Le-Mauff Brigitte Le-Mauff Jean-Baptiste Latouche Jean-Baptiste Latouche Olivier Toutirais Olivier Toutirais Olivier Toutirais HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy Frontiers in Immunology CD4+ T lymphocytes adoptive cell therapy cancer autoimmunity artificial antigen presenting cells HLA class II molecules |
author_facet |
Alexandre Couture Anthony Garnier Fabian Docagne Olivier Boyer Denis Vivien Denis Vivien Brigitte Le-Mauff Brigitte Le-Mauff Jean-Baptiste Latouche Jean-Baptiste Latouche Olivier Toutirais Olivier Toutirais Olivier Toutirais |
author_sort |
Alexandre Couture |
title |
HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy |
title_short |
HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy |
title_full |
HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy |
title_fullStr |
HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy |
title_full_unstemmed |
HLA-Class II Artificial Antigen Presenting Cells in CD4+ T Cell-Based Immunotherapy |
title_sort |
hla-class ii artificial antigen presenting cells in cd4+ t cell-based immunotherapy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2019-05-01 |
description |
CD4+ T cells differentiate into various T helper subsets characterized by distinct cytokine secreting profiles that confer them effector functions adapted to a variety of infectious or endogenous threats. Regulatory CD4+ T cells are another specialized subset that plays a fundamental role in the maintenance of immune tolerance to self-antigens. Manipulating effector or regulatory CD4+ T cells responses is a promising immunotherapy strategy for, respectively, chronical viral infections and cancer, or severe autoimmune diseases and transplantation. Adoptive cell therapy (ACT) is an emerging approach that necessitates defining robust and efficient methods for the in vitro expansion of antigen-specific T cells then infused into patients. To address this challenge, artificial antigen presenting cells (AAPCs) have been developed. They constitute a reliable and easily usable platform to stimulate and amplify antigen-specific CD4+ T cells. Here, we review the recent advances in understanding the functions of CD4+ T cells in immunity and in immune tolerance, and their use for ACT. We also describe the characteristics of different AAPC models and the way to improve their stimulating functions. Finally, we discuss the potential interest of these AAPCs, both as fundamental tools to decipher CD4+ T cell responses and as reagents to generate clinical grade antigen-specific CD4+ T cells for immunotherapy. |
topic |
CD4+ T lymphocytes adoptive cell therapy cancer autoimmunity artificial antigen presenting cells HLA class II molecules |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2019.01081/full |
work_keys_str_mv |
AT alexandrecouture hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT anthonygarnier hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT fabiandocagne hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT olivierboyer hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT denisvivien hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT denisvivien hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT brigittelemauff hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT brigittelemauff hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT jeanbaptistelatouche hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT jeanbaptistelatouche hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT oliviertoutirais hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT oliviertoutirais hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy AT oliviertoutirais hlaclassiiartificialantigenpresentingcellsincd4tcellbasedimmunotherapy |
_version_ |
1725997800121958400 |